Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company specializing in pharmaceutical preparations, announced the approval of its 2025 Stock Option and Incentive Plan (the "2025 Plan") during its Annual Meeting held on June 12, 2025. The 2025 Plan, which was previously approved by the Board of Directors, effectively replaces the company’s 2015 Stock Option Plan. The 2025 Plan will govern future awards, while the 2015 Plan will continue to apply to awards already granted.
At the same Annual Meeting, shareholders elected seven director nominees to serve until the 2026 annual meeting or until their successors are elected. The company also reported the ratification of Baker Tilly US, LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
The detailed results of the Annual Meeting voting included overwhelming support for the re-election of directors and the ratification of the accounting firm. The 2025 Plan was also approved with a significant majority, though with a higher number of abstentions compared to the other proposals. Notably, broker non-votes were recorded for the election of directors and the approval of the 2025 Plan.
This information is based on the latest 8-K filing by ProMIS Neurosciences Inc. with the Securities and Exchange Commission. The company continues to be incorporated in Ontario, Canada, with its shares traded on the Nasdaq Capital Market under the ticker symbol PMN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.